• Product NameGatifloxacin
• Brief DescriptionInhibitors
• Purification99.96%
• Biological ActivityGatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin? for the treatment of respiratory tract infections, having licensed the medication from Kyorin Pharmaceutical Company of Japan. Allergan produces an eye-drop formulation called Zymar?. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy.
• Target NameTopoisomerase inhibitor
• CAS No. 112811-59-3
• Calculated MW 375.4
• Formulation C19H22FN3O4
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Immunology
  SMILES:COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1
  Pathways:DNA Damage/DNA Repair
  Receptor:Topo IV
  Boling pt:607.8C
  Melting pt:162C
  Solubility:DMSO: 7 mg/mL (18.64 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Rafii F, et al. Antimicrob Agents ChemOthers. 2005 Feb;49(2):488-92.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting